The 2008 List offers some changes compared to the 2007 List. For example, the 2008 List will include new classes of substances such as selective androgen receptor modulators (SARMs), a family of nonsteroidal molecules that has the same effect as anabolic steroids, and agents modifying myostatin functions including but not limited to myostatin inhibitors. The Executive Committee also approved amending the prohibition of intravenous infusions so that intravenous infusions are not permitted except in the treatment of acute medical conditions.
The new List will be published online at the WADA website as well as the IPC website by 1 October 2007 and will go into effect on 1 January 2008.
WADA assumed responsibility for the List following implementation of the World Anti-Doping Code (Code) and the International Standards in 2004. The List is developed through a highly consultative yearlong process, beginning with the circulation of a draft List among more than 1,700 stakeholders, including the International Paralympic Committee (IPC), for comment. The comments received are processed by WADA's List Committee, who then presents its conclusions to the WADA Health, Medical and Research Committee, who in turn submits its final recommendations to the Executive Committee at the annual meeting. The Executive Committee, WADA's ultimate policy-making body, discusses the recommendations and makes a final decision.
For more information, please visit the official WADA website at www.wada-ama.org.